A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2017
Price : $35 *
At a glance
- Drugs PIM 447 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Novartis
- 22 Aug 2017 Status changed from active no longer recruiting to discontinued.
- 19 May 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2015 Planned End Date changed from 1 Feb 2018 to 1 Jan 2017, as reported by ClinicalTrials.gov.